Places for the PharmaTimes Marketer of the Year competition are filling up fast, so if you already know you want to take part, fill out our short online form today to secure your place.
News
AZ, MSD’s Lynparza/abiraterone combo hits prostate cancer goals
AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival in prostate cancer patients taking a combination of Lynparza and abiraterone.
NICE rules against first-line use of Ipsen’s Cabometyx
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
EU filing for Clovis’ Rubraca in ovarian cancer maintenance setting
Clovis Oncology is seeking to expand use of its PARP inhibitor Rubraca in Europe to include maintenance treatment of certain adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
BMS’ Opdivo cuts risk of melanoma recurrence
Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence, may significantly cut the risk of patients’ cancer returning.
US OKs first biosimilar of Amgen’s Neulasta
Mylan and Biocon’s Fulphila has become the first biosimilar of Amgen’s Neulasta to be approved by the US Food and Drug Administration.
Trial first to show immunotherapy benefit in prostate cancer
An international trial led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust has shown that immunotherapy can benefit men with prostate cancer.
MSD’s Keytruda takes lead in squamous NSCLC trials
MSD’s Keytruda has shown a greater benefit than Roche’s Tecentriq in separate (and incomparable) clinical trials exploring the effectiveness of the anti-PD-1 therapies in treatment-naiive patients with squamous non-small cell lung cancer.
US approves Lilly/Incyte’s Olumiant
As expected, US regulators have approved the lower dose of Eli Lilly/Incyte’s once-daily JAK inhibitor Olumiant as treatment for rheumatoid arthritis (RA).
Novartis’ Aimovig leads CHMP recommendations
The European Medicines Agency’s Committee for Medicinal Products for Human Use has endorsed nine medicines for approval at its May meeting, including Novartis’ Aimovig, the first human monoclonal antibody for migraine prevention.
Tesaro’s ovarian cancer drug Zejula added to Cancer Drugs Fund
Drug is first PARP inhibitor shown to be effective in both patients with and without a BRCA mutation
EMA facing higher-than-expected staff losses after Brexit
Executive Director Guido Rasi says that hitting 19% staff loss figure will be “very challenging”
Roche ends development of olesoxime after “many difficulties”
The company acquired the spinal muscular atrophy drug from Trophos for €120 million in 2015
Antibiotic supply chains on ‘brink of collapse’
Access to Medicine Foundation warns that urgent action is needed to rebuild the antibiotics market
Pfizer’s Xalkori makes it onto Cancer Drugs Fund
NICE has said that evidence is limited for the drug’s effectiveness in treating ROS1-positive lung cancer
